Support for induction of immune responses to neoantigen epitopes or highly networked epitopes comes from recent studies showing that a synthetic DNA, multi-neoantigen cancer vaccine in a mouse model drives robust MHC class I CD8+ T-cell responses which are able to impact tumor growth (198). This evidence concerns the gene CD8A and neoplasm.